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Abstract
Background: Perlecan is a proteoglycan expressed in the basal lamina of the neuroepithelium
during development. Perlecan absence does not impair basal lamina assembly, although in the 55%
of the mutants early disruptions of this lamina conducts to exencephaly, impairing brain
development. The rest of perlecan-null brains complete its prenatal development, maintain basal
lamina continuity interrupted by some isolated ectopias, and are microcephalic. Microcephaly
consists of thinner cerebral walls and underdeveloped ganglionic eminences. We have studied the
mechanisms that generate brain atrophy in telencephalic areas where basal lamina is intact.
Results: Brain atrophy in the absence of perlecan started in the ventral forebrain and extended to
lateral and dorsal parts of the cortex in the following stages. First, the subpallial forebrain developed
poorly in early perlecan-null embryos, because of a reduced cell proliferation: the number of cells
in mitosis decreased since the early stages of development. This reduction resulted in a decreased
tangential migration of interneurons to the cerebral cortex. Concomitant with the early hypoplasia
observed in the medial ganglionic eminences, Sonic Hedgehog signal decreased in the perlecan-null
floor plate basal lamina at E12.5. Second, neurogenesis in the pallial neuroepithelium was affected
in perlecan deficient embryos. We found reductions of nearly 50% in the number of cells exiting
the cell cycle at E12–E13. The labeling index, which was normal at this age, significantly decreased
with advancing corticogenesis. Moreover, nestin+ or PCNA+ progenitors increased since E14.5,
reaching up to about 150% of the proportion of PCNA+ cells in the wild-type at E17.5. Thus,
labeling index reduction together with increased progenitor population, suggests that atrophy is the
result of altered cell cycle progression in the cortical progenitors. Accordingly, less neurons
populated the cortical plate and subplate of perlecan-null neocortex, as seen with the neuronal
markers β-tubulin and Tbr1.
Conclusion: As a component of the basal lamina, perlecan both maintains this structure and
controls the response of the neuroepithelium to growth factors. Less mitotic cells in the early
medial ganglionic eminences, and impaired cell cycle progression in the late neocortex, suggests
insufficient recruitment and signaling by neurogenic morphogens, such as SHH or FGF2.
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Background
During the histogenesis of the cerebral cortex, neural pre-
cursor cells in the anlage of the cortical hemispheres as
well as in the subpallium withdraw from the cell cycle and
migrate in an ordered manner following multidirectional
pathways to generate a functional neuronal architecture
[1]. Proliferation and cell fate determination in the devel-
oping brain are extrinsically regulated by multiple interac-
tions among a large number of secreted molecules, such as
Sonic Hedgehog (SHH), epidermal growth factor (EGF),
and fibroblast growth factors (FGFs) [2,3], which usually
act in a concentration-dependent manner. The concentra-
tions of these morphogens are modulated in turn by com-
ponents of the extracellular matrix (ECM).
Perlecan is one of the most ubiquitous and multifunc-
tional ECM proteins. The proteoglycan is expressed during
the prenatal stages of brain development in the basal lam-
inae of the neuroepithelium and of blood vessels [4]. Per-
lecan binds with varying avidity to many diverse
macromolecules. These include cell-surface receptors such
as  β1 and β3 integrins [5,6] and α-dystroglycan [7,8];
other ECM proteins such as nidogen, collagen IV, laminin,
fibulin and fibronectin [9-11]; a number of signaling mol-
ecules such as FGF2 [12], FGF7 [13], platelet-derived
growth factor B (PDGF-B) [14] and Sonic Hedgehog
(SHH) [15]; and enzymes such as acetyl cholinesterase
[16]. In particular, it is well known that the heparan sul-
fate (HS) moieties of perlecan interact with growth fac-
tors, regulating their interaction with cell surface receptors
[17].
Analysis of perlecan-null mice has demonstrated essential
roles of this proteoglycan during development [4,18,19].
The absence of perlecan does not compromise assembly
of basement membranes. However, perlecan-deficient
embryos showed severe chondrodysplasia, life-threaten-
ing malformations of the heart outflow tract, as well as
impaired telencephalic development. Perlecan-null mice
die before birth due to their bone and heart malforma-
tions.
In a previous publication, we reported that many of
homozygote perlecan-null embryos presented exenceph-
aly [4]. We showed that exencephaly was not due to
impaired neural tube closure, but to an ulterior disruption
of the developing cerebral cortex caused by the invasion of
neural cells into the meningeal layers [4]. Interestingly,
even perlecan-null embryos without exencephaly showed
manifold morphogenetic alterations of the brain. This
observation suggested that these embryos might serve to
analyze major physiological functions of the protein in
telencephalon morphogenesis. In the present investiga-
tion, we studied in detail brain development in perlecan-
null embryos that do not show exencephaly. We conclude
that perlecan potentiates cell cycle progression and neuro-
nal differentiation in the cerebral hemispheres and ventral
forebrain. Our data suggest that perlecan could critically
regulate the availability of a crucial morphogen, such as
SHH, in the floor plate.
Results
Two brain phenotypes converge in perlecan-null embryos
In the present analysis, we selected perlecan-deficient
embryos that were not exencephalic. Whilst all homozy-
gote perlecan-null embryos depicted cerebral ectopias,
only about the 55% developed exencephaly. Ectopias are
invasions of the meningeal layers by neuroblasts after the
disruption of basal lamina. As previously reported, in the
most early (about E10.5) and severe cases these invasions
opened the neural tube in the frontal part of the cerebral
hemispheres [4] driving to exencephaly, which prevents
the brain to complete its development. Milder ectopias
did not induce de novo generation of cortical openings. In
these cases, ectopic cells did not proliferate and remained
trapped within the marginal zone generating distortion of
the cortical layers but allowing the brain to complete
development. Non-exencephalic embryos, which repre-
sent the remaining 45% of the perlecan-deficient
embryos, invariably displayed a hypoplasic brain pheno-
type. Typically, in these animals we observed the cerebral
cortex to proceed along development. It showed an obvi-
ous lamination, with a clear differentiation of cortical
compartments such as preplate and, later, marginal zone,
subplate and the cortical plate. Occasionally, and most
commonly near the rostral pole of the telencephalon, iso-
lated ectopias were evident. We considered these brains
useful to analyze critical functions of perlecan during cor-
ticogenesis. As a control in assessing such a hypoplasic
phenotype, after a visual inspection of the embryos, we
sectioned the brains serially and observed all the sections
carefully. We discarded as exencephalic those brains
showing openings of the cerebral wall. For the current
investigation, we have analyzed 24 perlecan-null non-
exencephalic embryos and 36 wild-type ones, ranging
from embryonic day (E) 10.5 to E17.5, distributed in 18
litters.
Non-exencephalic perlecan-deficient embryos are 
microcephalic
The non-exencephalic perlecan-null embryos showed
drastic reductions in the size of telencephalon. It is impor-
tant to recall that perlecan-null embryos do not display
reductions in the size of the rest of the body [4]. Fig. 1
shows coronal sections of E13.5 wild-type (A-C) and per-
lecan-null (D-F) telencephalon at different anteroposte-
rior levels. Figure 1G illustrates the comparison of the
cross-sectional areas of the cortical primordium (Ctx), lat-
eral ganglionic eminence (LGE) and medial ganglionic
eminence (MGE) measured in sections similar to those inBMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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Figure 1B and 1E. At E12.5 and E13.5, the overall mor-
phology was normal in the mutant telencephalon.
Although there were pallial reductions in some cases, a
constant underdevelopment was evident in the MGE and
the rostral part of hippocampus primordium (Hp). In all
perlecan-null embryos, the MGEs cross-sectional area
ranged between 24% and 70% of that of wild-type
embryos of the same litters. At E15.5, LGE in addition to
the MGE (Fig. 1H – I) and the CGE (not shown) showed
striking reductions in size as compared with wild-type lit-
termates. Moreover, at this stage, neocortex and paleocor-
tex primordia were markedly thinner.
In the E17.5 perlecan-null embryos (Fig. 1J – M), the
cross-sectional area of the brain was reduced to about
80% of that in their wild-type littermates. At this age,
brain reduction resulted mainly from a decrease in the
cross-sectional area of the ventral telencephalon, but also
the cerebral wall was significantly thinner mainly due to
reduced cortical plate thickness (Fig. 1L – M). In addition,
a number of ectopias were visible in the cortical plate,
which distorted the cortical laminar pattern (arrows in
Fig. 1K). The ectopias consisted of groups of early-gener-
ated neurons that invaded the meningeal layers disrupting
the basal lamina, as shown by laminin immunostaining
(Fig. 1N – O). This figure shows that in both perlecan-null
embryos and wild-type littermates, basal lamina assem-
bled normally in the cerebral surface (Fig. 1P).
In conclusion, the perlecan-null embryos that complete
their prenatal development were microcephalic. The cere-
bral hypoplasia progressed following a ventromedial-to-
laterodorsal sequence along brain development. The
brains maintained basal lamina continuity, interrupted by
some isolated ectopias.
The cell proliferation in the forebrain decays in the 
absence of perlecan
To understand the cellular mechanisms involved in the
brain hypoplasia, we measured proliferation in the ven-
tricular (VZ) and subventricular zones (SVZ) of the pal-
lium and subpallium. To this purpose, we first used an
antibody to the M phase marker histone H3 phosphor-
ylated on Ser 10 [20] (Fig. 2A – B). We quantified the
mitotic index as the ratio between the number of met-
aphase phospho-histone H3+ (pH3+) cells referred to the
number of progenitor cells in the same area, marked with
antibodies to Ki67 (Fig. 2C; see Methods). We found that
cells in metaphase distributed uniformly along the ven-
tricular surface of the telencephalic vesicles until E12.5
(data not shown). At E13.5 (Fig. 2A – B), a secondary
mitotic population, called basal progenitors, appeared in
the SVZ of the cortical primordium. In parallel with the
progression of hypoplasia, the mitotic index was reduced
in the perlecan mutants, starting in the medio-ventral tel-
encephalon and reaching the cortex at advanced cortico-
genesis. At E13.5, the perlecan-null brains had a mitotic
index similar to that of wild-type embryos in the cortex,
but displayed a reduced index in the MGE (2.6% in perle-
can-null mice vs. 4.0% in wild-type mice; Fig 2C). At
E16.5, the mitotic index was reduced in the perlecan-null
neocortex to about a 60% of that in the wild-type, and the
reduction affected both the VZ and the SVZ (basal) pro-
genitors (Fig. 2C). Thus, reduced proliferation seemed to
contribute to brain hypoplasia.
Together with the decay in the mitotic index, an aug-
mented rate of programmed cell death may also account
for the reduced brain size. We examined the telen-
cephalon for the presence of DNA fragments that are
direct evidence of programmed cell death using TUNEL
staining. No significant changes in the number of TUNEL+
cells were detectable in the neocortex and basal ganglia of
perlecan-null embryos. In Fig. 2D,E we show the TUNEL
stained neocortex of E15.5 wild-type and perlecan-null
embryos. At this age, few apoptotic cells were detectable
by TUNEL staining in the developing cortex, and we
observed no significant differences in the perlecan-null
embryos. Thus, cell death must not be a major agent in
generating underdeveloped cerebral walls and subpallium
in perlecan mutants. However, the contribution of cell
death to brain hypoplasia cannot be discarded com-
pletely, since it is known that the TUNEL method does not
detect all cells that die during prenatal development [21].
In the perlecan-null neocortex, the labeling index is 
normal at the beginning of cortical neurogenesis, but 
decreases at late stages
The impaired mitotic index observed in the pallium sug-
gests that low proliferation of cortical progenitors in the
VZ and SVZ might contribute to the reduction of cortical
size. The onset of such a process of low proliferation in the
cerebral wall occurred at the time corticogenesis is well
advanced, i.e., later than in the ventral forebrain. We stud-
ied in detail proliferation and neuronal differentiation in
the cortex at two representative time points: E12.5–E13.5,
which represents an early stage of corticogenesis, and
E16.5, which represents a late stage.
To analyze the rates of proliferation of neuronal precur-
sors in the cortical primordium, we used BrdU pulse labe-
ling and survival periods of either 30 min, 4, or 24 hours
combined with Ki67 staining (Fig. 3). Thirty min after a
BrdU pulse, BrdU-labeled cells appeared distributed
throughout the VZ and SVZ (Fig. 3A – B). At E13.5 there
was no change in the distribution and quantity of BrdU-
labeled cells (data not shown). However, as shown in Fig.
3A and 3B, at E16.5 both VZ and SVZ contained less
BrdU+ cells in the perlecan-null embryos than in the wild-
type littermates. Twenty four hours after a BrdU pulseBMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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Microcephaly in perlecan-null embryos Figure 1
Microcephaly in perlecan-null embryos. (A-F) Series of Nissl stained coronal sections of E13.5 forebrain at rostral (A, D), 
middle (B, E) and caudal (C, F) levels. The brains of a wild-type (A-C) and a perlecan-null (D-F) embryos are shown. Note a 
reduction in the size of the ventral forebrain in the perlecan-null brains, particularly affecting the medial structures, such as 
MGE, hippocampus, and rostral part of the thalamus. (G) Quantification of pallial, MGE and LGE cross-sectional area per hem-
isphere in sections at the middle level. Results reveal that whole brain size is reduced variably in perlecan-null embryos, but 
that at E13.5 all perlecan-null embryos have severely underdeveloped MGE as compared with their wild-type littermates. Two 
litters at E12.5 and three litters at E13.5 were used; n = 2 embryos at E12.5 and n = 6 embryos at E13.5. ** p < 0.01. (H, I) Nissl 
stained coronal sections at E15.5 in wild-type (H) and perlecan-null (I) embryos. Ventral forebrain underdevelopment extends 
significantly to LGE and paleocortex. Note the reduction of cortical plate thickness in the perlecan-null cortex. (J-M) E17.5 
wild-type (J, L) and perlecan-null (K, M) embryos. Panels L and M represent enlargements of the regions boxed in J and K, 
respectively. The ventral forebrain is reduced in size in the perlecan-null embryo, and the cortical plate is thinner. Additionally, 
in the perlecan-null telencephalon, the onset of neuronal ectopias (arrows in K) is frequent in the most antero-dorsal region of 
the cerebral hemispheres. (N-P) Antibodies to laminin highlight the meningeal basal lamina, the meninges and the blood vessels 
in the wild-type (N) and perlecan-null (O and P) embryos. In the perlecan-null, disruption of the basal lamina is observed in an 
ectopic area (indicated by arrows in O). However, in the rest of the basal surface of the perlecan-null brain, laminin deposition 
is continuous (P). Scale bars: 250 μm (A-F, H-I), 500 μm (J, K), 50 μm (L, M), 40 μm (N-P). Abbreviations: CGE, caudal gangli-
onic eminence; CP, cortical plate; Hp, hippocampus; IZ, intermediate zone LGE, lateral ganglionic eminence; MGE, medial gan-
glionic eminence; P, pallium; Th, thalamus.BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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(Fig. 3C–F), a dense cell layer appeared between the VZ
and SVZ (arrow in Fig. 3C,E). The cells of this layer were
BrdU+ but Ki67- and, thus, newborn neurons; they were
less abundant in the perlecan-null embryos (Fig. 3D,F).
We calculated the labeling index in non-ectopic areas of
the neocortical primordium of perlecan-null embryos, in
one litter at E12.5, four litters at E13.5 and two at E16.5
(Fig. 3G), and results were compared to mean values of
two wild-type embryos from each litter. Labeling index is
the number of BrdU+ cells divided by the number of Ki67+
cells (see Methods).
At E12.5 and E13.5, after different survival times to BrdU
pulses, we observed an unaltered labeling index in perle-
can-null embryos. However, at E16.5, the labeling index
decreased significantly to about 50% in the perlecan-null
embryos (Fig. 3G). This was due to both a decrease in the
number of BrdU+ cells and to a moderate increase in the
size of the progenitor Ki67+ population. In conclusion,
the decrease in the labeling index indicates that the cell
cycle lengthened abnormally in perlecan-null embryos as
corticogenesis proceeds.
Since the earliest steps of cortical neurogenesis, the 
fraction of cells exiting the cell cycle decreases in the 
neocortex of perlecan-null embryos
To analyze neuronal differentiation, we measured the
quitting fraction, i.e., the fraction of cells leaving the cell
cycle at a given time point. We selected two E13.5 litters,
with two and three perlecan-null embryos each, because
cortical neurogenesis is already massive in the wild-type
neocortex at this age. We applied a pulse of BrdU and col-
lected the tissue 24 hours later (Fig. 4A – B). We calculated
the cell cycle quitting fraction as the proportion of BrdU+/
Ki67- postmitotic cells among all BrdU+ cells (Fig. 4C). In
the perlecan-null embryos, the quitting fraction reached
only a 30–70% of the value for wild-type littermates.
Taken together, these results showed that, although the
rate of proliferation decayed progressively as corticogene-
sis proceeds, neuronal differentiation was impaired in the
cortical primordium of perlecan-null embryos already at
the earliest stages.
The proliferation rate of mammalian cells is generally reg-
ulated in the G1  phase of the cell cycle. It has been
reported that an heparan sulfate-binding growth factor,
FGF2, could modulate G1/S transition in cerebral cortex
[22]. To test whether the absence of perlecan provokes a
lengthening of G1, we approached the problem indirectly
by measuring the length of G2. We administered a pulse of
BrdU to one dam at E16.5 and collected the tissue 2 hours
later; we used such a survival time since it has been estab-
lished that G2/M lasts for about 2 hours at this embryonic
Cell proliferation decays in the absence of perlecan Figure 2
Cell proliferation decays in the absence of perlecan. 
(A, B) Mitotic cells in M phase immunodetected with an anti-
phospho-histone H3 antibody in the telencephalic vesicles of 
E13.5 wild-type (A) and perlecan-null (B) embryos. The neo-
cortex shows two well-differentiated mitotic populations: 
the ventricular primary population in the VZ, and the basal 
progenitors in the SVZ that emerges in the middle of the pal-
lium at E13.5. (C) The mitotic index (the percentage of phos-
pho-histone H3-labeled cells among Ki67+ progenitors) 
shows significant differences in the MGE, but not in the neo-
cortex at E13.5. At E16.5, the mitotic index in the neocorti-
cal primordium is reduced to about a 60% of that in wild-type 
embryos, affecting both the VZ and the SVZ mitotic popula-
tions. Values are the mean ± SEM, n = 5 at E13.5; n = 4 at 
E16.5. * p < 0.05; ** p < 0.001. (D, E) TUNEL staining of 
E15.5 wild-type (D) and perlecan-null (E) dorsal neocortex. 
As in the wild-type littermates, very few TUNEL-positive 
cells (arrows in D and E) were observed in perlecan-null 
embryos. Scale bars: 150 μm (A, B), 80 μm (D, E).BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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The labeling index is normal at the beginning of cortical neurogenesis, but decreases at late stages in the perlecan-null neocor- tex Figure 3
The labeling index is normal at the beginning of cortical neurogenesis, but decreases at late stages in the per-
lecan-null neocortex. (A-D) Immunofluorescence for BrdU (green) in the cortical primordium after a 30 min (A, B) and a 24 
hours (C, D) survival to a BrdU pulse in wild-type (A, C) and perlecan-null (B, D) E16.5 embryos. In both cases, less BrdU+ cells 
are seen in the perlecan mutants. (E-F) Double immunofluorescence for BrdU (green) and Ki67 (red) in the pallium of E16.5 
wild-type and perlecan-null embryos after a 24 h survival to a BrdU pulse at E15.5. Note the panels are high magnification views 
of the boxed areas in C, D. Observe abundant double-labeled cells (yellow) in the VZ and a thick layer containing BrdU+ cells 
(and no Ki67+ cells) in the SVZ of wild-type embryos, corresponding to the newly generated neurons (arrow in C and E). 
Observe the reduced BrdU incorporation in the perlecan-null dorsal cortex, affecting both the VZ and the SVZ. (G) Labeling 
index (the percentage of BrdU+ cells among Ki67+ progenitors) in cortical sections after 30 min, 4 hours and 24 hours survival 
to a BrdU pulse at E12.5, E13.5 or E16.5. Means ± SEM values are shown. n = 2 embryos for E12.5; n = 4 for E13.5 BrdU 4 h; n 
= 5 for E13.5 BrdU 24 h; n = 2 for E16.5 BrdU 30 min; and n = 2 for E16.5 BrdU 24 h. ** p < 0.001. No significant changes of 
labeling index are evident in the perlecan-deficient embryos at E12.5 and E13.5, but at E16.5 the index is significantly reduced. 
Scale bars: 100 μm (A-D), 40 μm (E, F).BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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age [23,24]. Phosphorylation on Ser10 of histone H3 is
required for chromosome condensation during prophase.
Using antibodies to pH3, a punctate nuclear labeling
occured during late G2, to become homogeneous during
the M phase (arrows in Fig. 4D). We measured the fraction
of cells double-labeled with pH3 and BrdU in the cortical
primordium (Fig. 4D – F). In this experiment, nuclei dou-
ble-labeled with pH3 and BrdU were the nuclei in M
phase that were in S phase at the time of the BrdU pulse.
We referred the total number of double-labeled cells to
the total number of BrdU+ cells in the same section. The
proportion was of 16.9 ± 5.3% in two wild-type embryos
and of 20.9 ± 7.9% in one perlecan-null embryo (n = 12
sections), but differences were non-significant. Therefore,
the length of G2/M phase did not change in the perlecan-
null embryos at E16.5 and, thus, could not contribute to
the detected decay in proliferation rate. Thus, we conclude
that the lengthening of the cell cycle, which indicates an
impairment of normal cell cycle progression, was mostly
due to the lengthening of G1 phase.
Perlecan deficiency alters the size of the neural progenitor 
population in the ventricular zone
As described above, we observed an increase in the pro-
portion of progenitor cells labeled by Ki67 antibodies,
and that cell proliferation rate diminished, in perlecan-
null embryos (Fig. 3E – G). Like Ki67, PCNA is a nuclear
protein that is expressed during all phases of the cell cycle
[25,26]. We used this antibody to calculate the percentage
of cycling cells among the total number of Nissl-stained
cells present in the neuroepithelium of the hippocampal
and neocortical primordia at E17.5 (Figs. 5A – D). PCNA+
cells represented a 4 ± 0.9%, in wild-type embryos and a
6 ± 0.5% in the perlecan-null embryos (n = 2 embryos, p
< 0.01). This difference started at E14.5 (30.7 ± 0.2% vs.
38.9 ± 0.7%; n = 2 embryos, p < 0.05), but was non-signif-
icant at E12.5–E13.5.
Defective neurogenesis in the pallium of perlecan-deficient embryos Figure 4
Defective neurogenesis in the pallium of perlecan-deficient embryos. (A, B) Double immunofluorescence for Ki67 
(red) and BrdU (green) after 24 hours survival to a E12.5 BrdU pulse was used to calculate the fraction of cells exiting the cell 
cycle (quitting fraction) at E13.5. Cells labeled only with BrdU, a pool no longer dividing, are abundant in the cortical plate in 
the wild-type embryos (CP in A), but its number in the perlecan-null neocortex decreases considerably (B). (C) Quantification 
of the fraction of cells leaving the mitotic cycle (quitting fraction: percentage of the number of BrdU+, Ki67- cells among the 
total of BrdU+ cells) in two E13.5 litters. In the perlecan mutants, the number of cells that leave the cell cycle is reduced to 
approximately a half of that in wild-type littermates, n = 6 slices.* p < 0.05 and ** p < 0.01. (D, E) Double labeling with phos-
phorylated histone H3 (red) and BrdU (green) after 2 hours survival to a BrdU pulse, used to compare G2/M phase in wild-type 
(D) and perlecan-null (E) neocortex at E16.5. (F) Quantification of the percentage of cells in G2/M cell cycle phase (double 
labeled cells; arrows in D) referred to the total of BrdU labeled cells. n = 12 slices. Scale bar: 40 μm (A, B, D, E).BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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Perlecan deficiency increases the cortical progenitor pool Figure 5
Perlecan deficiency increases the cortical progenitor pool. (A-D) Immunostaining for PCNA, a cell cycle marker, in 
coronal sections of wild-type (A, C) and perlecan-null (B, D) telencephalon at E17.5, Nissl counterstaining. Boxes in (A) and (B) 
are enlarged in (C) and (D) panels, respectively. (E-H) Nestin expression in coronal sections of wild-type (E, G) and perlecan-
null embryos (F, H) at E14.5 (E, F) and E17.5 (G, H). At E14.5, the processes of nestin+ radial glia cells in the marginal zone 
reach up the pial surface. Note the normal disposition of radial glia endfeet below the basal lamina (BL) in the perlecan-null 
embryo (F) and in the wild-type (E). Note the marked increase in immunostaining intensity of radial glia in the mutant at both 
ages. Abbreviations: HIP, hippocampus; nCTX, neocortex; Th, thalamus. Scale bars: 100 μm (A, B), 20 μm (C, D), 30 μm (E, F), 
50 μm (G, H).BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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The cortical neuroepithelium has two progenitor popula-
tions: radial glia and basal progenitors [27]. Nestin labels
radial glia, the progenitor cells in the VZ [28] that extend
long processes to the basal lamina. To confirm that perle-
can-null embryos had a more abundant progenitor cell
pool, we next analyzed nestin expression (Fig. 5E – H)
and, in agreement with the results with PCNA and Ki67,
nestin labeled the neocortical primordium more intensely
in perlecan-null than in wild-type embryos. At E14.5, sub-
pial terminations of nestin+ radial glia in the marginal
zone packed more densely in perlecan-null embryos (Fig.
5F), the same as nestin+ radial glia in the VZ at E17.5 (Fig.
5H).
Thus, results of nestin immunostaining were in accord
with the abnormally high proportion of VZ progenitor
population in the late perlecan null neocortex. It is worth
of note that both in perlecan-null and wild-type embryos,
radial glia terminations reached the basal lamina, indicat-
ing that anchoring of glial endfeet to the pial basal lamina
(Fig. 5F) occurred even in the absence of perlecan.
Different neuronal populations in the cerebral cortex show 
impaired differentiation in absence of perlecan
Next, we confirmed that neuronal differentiation was
impaired in perlecan-null cerebral wall. To this end, we
used antibodies to β-tubulin type III (Fig. 6A – D) and to
Tbr1 (Fig. 6E – F), two neuronal markers. In E13.5 wild-
type embryos, β-tubulin marked cells in the mantle of the
pallium (i.e. the cortical preplate) and of the septal and
ganglionic eminences (Fig. 6A). In the perlecan-null
embryos, in accord with the reduced cell cycle exiting pop-
ulation, the thickness of the β-tubulin+ layer was reduced
not only in the pallium (see also, Haubst et al., 2006
[29]), but also in the mantle of the septal and ganglionic
eminences (Fig. 6B). The decrease of neuronal differentia-
tion in the perlecan-null embryos was even more obvious
in the late developing stages. Thus, at E16.5 β-tubulin
marked cells within the marginal layer and the cortical
subplate (Fig. 6C). As shown in Figure 6D, β-tubulin
immunoreactivity in the subplate was significantly less
dense in the perlecan-null embryos than in the wild-type
littermates. Tbr1 is a T-box transcription factor expressed
by diverse populations of early-generated neurons of the
developing cerebral cortex [30,31], such as neurons of the
marginal zone (MZ), the subplate (SP) and deep cortical
plate (CP) (Fig. 6E). In the perlecan-null embryos, the
number of Tbr1+ neurons decreased both in the SP and in
the deep CP. In addition, Tbr1 labeling revealed that,
unlike in wild-type embryos, the subplate did not segre-
gate from the cortical plate in perlecan-null embryos (Fig.
6F). The neurons that populate the MZ and the SP initially
reside in the preplate, formed at about E12.5, so that these
results suggest that perlecan is critical for the differentia-
tion of the earliest generated neurons at this age. There-
fore, the decrease in the neuronal pool in the cortical
primordium of perlecan mutants could be due to the
impaired rate of differentiation of mitotic cells into post-
mitotic neurons.
The neocortex is formed mainly by radially migrating neu-
rons born in the pallial VZ and SVZ, but it also receives an
important contribution of tangentially migrating
interneurons generated in the ganglionic eminences of the
basal telencephalon [32] and in other prosencephalic
sources [33-35]. To understand how these neuron popu-
lations developed in absence of perlecan, we identified a
population of presumptive tangentially migrating
interneurons by calbindin (CB) immunostaining [32]
(Fig. 6G – H). At E17.5, CB+ neurons formed clusters in
the basal telencephalon and already distributed within
the cortical plate of wild-type brains (Fig. 6G). However,
we detected less CB+ neurons in the cortex of perlecan
mutants (Fig. 6H) than in the wild-type ones, most likely
a consequence of the early hypoplasia observed in the
MGE of perlecan-null embryos. Less tangential migration
could explain in part the reduction in the cerebral wall
thickness.
Perlecan deficiency alters the distribution of Sonic 
Hedgehog in the basal forebrain
Perlecan binds signaling molecules that play important
roles in forebrain patterning and neurogenesis, such as
FGF2 and SHH. FGF2 is a HS binding growth factor
involved in brain development. We compared the tissue
distribution of this protein in anterior sections of telen-
cephalon of perlecan-null and wild-type littermates
between E10.5 and E15.5. However, no changes in the
pattern of distribution between wild-type and perlecan-
null embryos were evident at any analyzed stage (data not
shown).
During early development, the prechordal plate beneath
the anterior part of the murine brain produces SHH. From
this area, the protein diffuses to the basal part of the fore-
brain and induces neurons of the ganglionic eminences to
initiate their own expression of SHH [36]. At E10.5, we
detected the presence of SHH protein in the floor plate
and in the medial aspect of the MGE (Fig. 7A, detail in
7C). In the perlecan-null embryos, the territory displaying
immunocytochemical signal was reduced (Fig. 7B – D). At
E12.5, we detected SHH immunostaining in the floor
plate and in the mantle of the MGE (Fig. 7E, detail in 7G),
extended caudally across the medial and caudal gangli-
onic eminences (not shown). In the E12.5 perlecan-null
embryos, SHH signal appeared more caudally than in the
wild-type (not shown), and the area of SHH signal was
reduced, as compared to wild-type littermates (Fig. 7F,
detail in 7H). This reduction was particularly evident at
the floor plate basal lamina (between arrows in Fig. 7E).BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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Less neurons and interneurons are present in the cortical primordium of perlecan-null embryos Figure 6
Less neurons and interneurons are present in the cortical primordium of perlecan-null embryos. (A-D) β-tubulin 
type III immunostaining at E13.5 (A, B) and at E16.5 (C, D). At E13.5, the telencephalic vesicles show immunoreactivity in the 
mantle of the cortical primordium and of the septal and ganglionic eminences. In the perlecan-null, the extension of β-tubulin 
immunoreactivity is reduced in the pallium and in the subpallium (arrows in B). At E16.5, neocortical β-tubulin expression is 
strong in the wild-type subplate (C) but clearly reduced in the perlecan mutants (D). (E, F) At E16.5, the transcription factor 
Tbr1 labels the nuclei of early-born neurons in MZ, CP and SP. In the perlecan-null embryos the number of Tbr1+ neurons 
decreases severely and the lower tier of the CP is indistinguishable from the SP (F). Note an ectopia at the right hand side of 
(F). (G, H) Cortical interneurons detected by calbindin immunohistochemistry at E17.5. Comparable rostro-caudal levels are 
shown. Note in the perlecan-null brain (H) a notorious descent of the packing density of calbindin-immunoreactive interneu-
rons that have invaded the subplate and cortical plate, as well as the hippocampus. Scale bars: 100 μm (A-D), 40 μm (E, F), 200 
μm (G, H). Abbreviations: CP, cortical plate; DTh, dorsal thalamus; Hp, hippocampus; IZ, intermediate zone; POC, primary 
olfactory cortex anlage; SP, subplate.BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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Laminin immunostaining shows the continuity of the
basal lamina in the floor plate both in wild-type (Fig. 7I)
and perlecan-null embryos (Fig 7J). This basal lamina is
the place of perlecan deposition (Fig. 7K). These results
support the hypothesis that perlecan may play a major
role in the regulation of SHH availability in the telen-
cephalon during the early stages of ventral brain develop-
ment.
We then analyzed the distribution of Patched 1 (Ptch1),
the receptor of SHH (Fig. 7L – O). At E12.5, both in wild-
type and in perlecan-null embryos, Ptch1 expression did
not exactly match SHH signal. In the midline, Ptch1
expression was absent. The LGE showed Ptch1 signal
whilst no SHH immunoreactivity was visible in this
region. As shown in detail in Fig. 7O, in the perlecan-null
embryos the Ptch1 signal in the floor plate was unaltered
in places where SHH was nearly absent. However, a less
intense Ptch1 immunoreactivity matched the strong
decrease of SHH signal in the mantle of the MGE. Thus, in
the perlecan mutants at E12.5, Ptch1 expression did not
match SHH expression in the floor plate, but it did in the
MGEs mantle.
Discussion
The role of the leptomeningeal basal lamina during brain
development remains controversial: whilst some research-
ers claim that it actively participates in the control of cell
proliferation and neuronal differentiation, others only
ascribe to it the passive function of maintaining brain
structure. In particular, laminin on the one hand and glial
integrins and α-dystroglycan on the other are required for
anchorage of glial endfeet to the pial basal lamina, and
mice defective in these proteins exhibit abundant ectopias
and disorganization of the cortical marginal zone [37-40].
In a previous work, we reported that perlecan-null
embryos present cortical ectopias or exencephaly. Further,
we showed that exencephaly is due to very early disrup-
tion of the cortical plate, caused in turn by invasion of
neurons into meningeal layers [4]. In the rest of perlecan
knockouts, ectopias set off at or before E12.5. With
advancing corticogenesis, the clusters of early-generated
neurons that form the ectopias settle abnormally and
remain trapped in the marginal zone of the cortex.
Among other components of the basal lamina, perlecan
bind cell receptors such as integrins and α-dystroglycan
[6,8]. However, and in marked contrast with laminin, α-
dystroglycan or β1-integrin, perlecan is not essential for
extracellular matrix (ECM) assembly [41], and a basal
lamina covers most of the cerebral surface of perlecan-null
embryos. Nevertheless, the ectopias that form in the per-
lecan mutants appear to result from defects in the struc-
ture of the perlecan-defective basal lamina.
In a recent paper, Gotz and co-workers reported that
mutant mice with defects in the continuity of the basal
lamina due to a mutated nidogen-binding site in laminin
γ1 chain, or to perlecan or α6-integrin knockouts, exhibit
normal neurogenesis and proliferation in the ectopic
areas where radial glia has lost contact with the basal lam-
ina [29]. These authors infer from these results that the
attachment of radial glia endfeet to the basal lamina does
not play an important role in the control of radial glia pro-
liferation and fate. This attachment could be, however,
functionally relevant for positioning neurons during their
radial migration [29]. Based on a much more extended
material, we show here that perlecan-null brains undergo
cortical neurogenesis indeed, but this process is severely
impaired since the earliest stages and implies profound
reductions in the thickness of the cortical plate. Moreover,
we show here that these alterations affect non-ectopic
areas, an aspect unanalyzed in their report. Along these
lines, it is also noteworthy that brains of mouse embryos
mutated in laminin γ1III4 chain or with a brain-selective
deletion of β1-integrin invariably exhibit significant
reductions in the size of the telencephalon [38,40]. We
consider that this hitherto unexplained defect and our
present observations are highly relevant to understand the
cues that link basal membrane and neurogenesis.
To ascertain in detail the developmental roles of perlecan
and of basal lamina in neurogenesis, we centered our cur-
rent analysis in brain areas that were devoid of ectopias. In
these regions, the basal lamina is present in the brain sur-
face, and radial glia endfeet are in their proper subpial
positions.
Regulation of neurogenesis by perlecan
Atrophy in the perlecan mutants is detectable much ear-
lier in the ventral telencephalon than in the cortical pri-
mordium and progresses in a medial-to-lateral direction.
Thus, between E12.5 and E13.5, the size of the medial
ganglionic eminence in perlecan-null embryos was
severely reduced, while those of the LGEs and dorsal tel-
encephalon were normal. During the following days, atro-
phy extended to the whole ventral telencephalon and
paleocortex. A compromised tangential migration of
MGE-derived interneurons [42] could perhaps account for
paleocortex atrophy. At intermediate stages (E15.5),
reduction in size of the ventral telencephalon provided an
elongated appearance to the neocortex. Such an elongated
aspect has also been described in laminin mutants [29],
and invoked to explain the reduction of cortical thickness
in these mutants. However, in the late (E17.5) perlecan-
null brains the neocortex is not more elongated than in
the wild-type, and the whole telencephalon is reduced in
size.BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
Page 12 of 17
(page number not for citation purposes)
During corticogenesis, cell cycle exit, neuronal differenti-
ation and migration are coordinately regulated. At E17.5,
the non-ectopic areas of the cerebral cortex of perlecan-
null brains had a normal layering thus implying normal
radial migration, but the cortical plate was strongly
reduced in thickness. The initial defect is a decay of neu-
ronal differentiation: at E13.5, the fraction of cells exiting
cell cycle reduced by nearly one-half of normal values in
perlecan-null embryos. In good correspondence, immu-
nostaining for Tbr1, which marks different populations of
early-generated neurons of the developing cerebral cortex,
and βIII-tubulin, a general neuronal marker, revealed a
reduction in the packing density of neurons in the perle-
can-null cortical plate and subplate. Finally, we found the
neocortex of perlecan-null embryos to have much less pre-
sumptive interneurons in the cortical plate than their
wild-type littermates. The decrease of interneurons is
probably the consequence of the initial atrophy that
occurs in the ventral forebrain, because the MGE is the
major source of tangentially migrating neurons bound to
the neocortex [32,43]. In apparent contradiction with the
reduced mitotic index, in the perlecan-null primordium
we have demonstrated a progressive increase in the pro-
portion of progenitor cells that express nestin or PCNA. At
E14.5 the proportion of PCNA+ cells, among the total cell
content, increased up to 127%, and at E17.5 reached up
to the 150% of the proportion in the wild-type litterma-
tes. These data denote an immature status of perlecan
defective brain at late corticogenesis.
We note that in other mice mutants, such as the αE-cat-
enin-deficient mice [44] and β-catenin overexpressing
mice [45], lack of neuronal differentiation results in big-
ger brains due to early increases of the progenitor popula-
Distribution of Sonic Hedgehog protein in the telencephalon of perlecan-null embryos Figure 7
Distribution of Sonic Hedgehog protein in the telencephalon of perlecan-null embryos. (A-H) SHH immunostain-
ing in the forebrain of wild-type (A, E) and perlecan-null (B, F) embryos at E10.5 (A-D) and E12.5 (E-H). C, D, G and H are 
higher magnifications of the boxed areas in A, B, E and F. In the absence of perlecan, the diffusion of SHH into the brain is still 
present, but there is a significant decrease in the signal intensity in the ventral telencephalon, especially in the medial ganglionic 
eminences. Note that the floor plate basal lamina shows a strong SHH immunostaining in the wild-type brain (arrows in C and 
G) whereas no signal is detectable in the perlecan-null embryos (D and H). (I-K) Laminin immunostaining shows basal lamina 
continuity in the E12.5 wild-type (I) and perlecan-null (J) floor plate. The deposition of perlecan immunostaining in wild-type 
embryo coincides with that of laminin (K). The region shown in I-K is the same shown between arrows in (G). (L-O) Immunos-
taining for Patched 1 (Ptch1), the receptor of SHH, in wild-type (L, N) and perlecan-null (M, O) brains at E12.5. Ptch1 distrib-
utes in the mantle of the ganglionic eminences and is absent in the midline, the site of strongest SHH signal. In the mutant there 
is normal distribution of Ptch1. Scale bars: 100 μm (A, B, E, F, L-O), 50 μm (C, D, G, H), 40 μm (I-K).BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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tion. This is in contrast to perlecan mutants, where the
progenitor population increases only during the most
advanced stages of corticogenesis, and the labeling index
diminishes concomitantly. This difference might well
explain the opposite phenotype observed in αE- and β-
catenin vs. perlecan mutant mice.
To understand this difference, it is important to stress that
in perlecan-null mice the labeling index is unaltered at the
onset (E12.5–E13.5) of corticogenesis, but it decreases as
corticogenesis proceeds. In mammalian cells, the length
of S phase remains relatively constant [46], and no
changes in the length of the G2/M phases were detectable
in perlecan-deficient neocortex. Thus, it seems likely that
the lengthening of cell cycle observed in the absence of
perlecan is due to an extension of the G1 phase. This
would in turn result in a progressively increasing fraction
of postmitotic cells that cannot become neurons and con-
tinue undifferentiated, but have lost the potential to initi-
ate a new S phase. This dormant Go  state has been
described in brain culture, but is considered an abnormal
fate option for neuronal precursors in the neuroepithe-
lium that may result from trophic factor deprivation [22].
We will further discuss this aspect below.
Hypoplasia could also result from an increase in the
number of dying cells in the perlecan-null brain. We did
not detect changes in the apoptotic cell population in the
cortex of perlecan mutants at E10.5–11.5 [4] and at E15.5
(present data). Blaschke et al. [21] identified a population
of dying cells among the progenitor pool in the develop-
ing cortical VZ that accounts an average of approximately
50% of the progenitor population. This population is
much larger than the apoptotic pool detected with the
standard method of TUNEL or with antibodies to acti-
vated caspase 3. Although a detailed study on this apop-
totic population in perlecan-null mice is necessary to
discard that cell death is playing a role in the cerebral
hypoplasia, the observed progressive increase of the pro-
genitor population seems to suggest that apoptosis is not
playing a relevant role in brain atrophy.
In summary, less proliferation in both the ventral telen-
cephalon and the cortex will result in decrease of tangen-
tially migrating neurons and less neuronal differentiation
in the cerebral cortex, respectively, and may explain the
outstanding reduction of cortical thickness that occurs in
these knockout mice.
What are the mechanisms by which perlecan promotes 
brain maturation?
Diverse morphogens modulate cell division and neuronal
fate in a concentration-dependent manner. Perlecan is a
large modular proteoglycan that possesses multiple func-
tions associated with both its protein and carbohydrate
moieties. In particular, the heparan sulfate chains of the
proteoglycan specifically bind two morphogens that are
likely candidates to explain the observed brain pheno-
type, namely Sonic hedgehog (SHH) [15] and fibroblast
growth factor-2 (FGF2) [12].
SHH is absolutely required for ventral brain expansion
and maturation [2,36,47,48], including the specification
of MGE-generated cortical interneurons [49]. In the perle-
can deficient embryos, brain atrophy starts at about E12.5
and has a ventromedial-to-lateral progression. SHH pro-
tein diffuses into the brain following a ventromedial-to-
lateral pattern, which coincides with the direction of brain
atrophy progression in perlecan-deficient embryos. The
strong immunocytochemical SHH signal found within
the floor plate and basal lamina at E10.5–E12.5 probably
reflects the fact that SHH is translocated into the brain,
where it forms active multimeric complexes [50]. In the
perlecan-null embryos, neither SHH distribution within
the neuroepithelium nor expression of its receptor, Ptch1,
was impaired.
However, a marked reduction in the intensity of the SHH
signal in the basal part of forebrain at E10.5–E12.5, and
the absence of SHH immunostaining in basal lamina of
the perlecan-null embryos suggests a role for the prote-
oglycan in the spreading of SHH complexes. Accordingly,
we propose that perlecan is required to concentrate SHH
signal in the floor plate, in order to facilitate its proper
delivery to the neural plate at the exact concentration and
time needed for correct brain development. Along these
lines, the perlecan homologue in Drosophila, trol, regulates
the timing of neuroblast proliferation by modulating FGF
and Hedgehog signals [15]. Further, SHH interactions
with heparan sulfate proteoglycans promote maximal
proliferation of postnatal granule cells [51]. In addition to
its role in ventral neural tube patterning, SHH participates
in the control of progenitor cell number in developing
dorsal brain. Although neither immunostaining nor in
situ hybridization allowed to detect SHH in this compart-
ment, more sensitive RT-PCR analyses indicate that SHH
is present in the neocortex since E14.5 [52]. This possibil-
ity is compatible with our data showing the presence of
the SHH receptor Ptch1 in the neocortex. The retarded dif-
fusion of SHH into the perlecan-null cerebral wall could
explain the delayed atrophy in this compartment in
mutant mice. Nevertheless, additional direct evidence is
still needed to conclusively establish that cerebral hypo-
plasia in the perlecan mutants is secondary to delayed
SHH signal.
In addition to SHH, FGF signaling is required both for
generating ventral precursors and for promoting their dif-
ferentiation in the telencephalon, as nicely shown in the
FGFR1; FGFR2 double mutant [53]. Mice lacking FGF2BMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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exhibit a reduced density and number of neurons in the
neocortex [54-56], and microinjection of FGF2 into the
cerebral ventricles shortens the cell cycle and increases the
number of cortical neurons [57]. In addition, the pallial
defect of perlecan-null embryos strongly resembles that
seen in mice with a conditional disruption of EXT1, the
HS-polymerizing enzyme, which show an abnormally
small cerebral cortex [58]. Therefore, less commitment to
a neuronal fate in the perlecan knockouts could alterna-
tively result from defective FGF2 signaling of the VZ pro-
genitors in the cerebral wall. Admittedly, we did not detect
overt changes in the intensity or pattern of distribution of
FGF2 protein in the telencephalon of perlecan mutants.
However, we note that growth factors such as FGF2 are
required in very low amounts, undetectable by standard
procedures, to activate signaling. Regulation of cell cycle
and commitment to neuronal differentiation takes place
before the last division of progenitors and during the fol-
lowing G1 [59]. Radial glia, as neural progenitor cells in
the VZ [28,60-62], extend and retract basal processes to
attach and detach from the basal lamina in a cell cycle-
dependent sequence. In particular, VZ progenitors interact
strongly with the basal lamina during G1, and perlecan-
bound FGF2 could directly promote progression along
the cell cycle and neuronal commitment at this stage.
Conclusion
In summary, we show that perlecan influences the size of
ventral and cortical telencephalic structures. Brain atrophy
starts in the ventral telencephalon, with a marked reduc-
tion of basal progenitor proliferation, and progresses in a
medial-to-lateral direction. Our findings suggest insuffi-
cient recruitment and/or signaling by the morphogen
SHH, in the basal lamina of the floor plate. In addition, in
the cortex the presence of perlecan in the leptomeningeal
basal lamina could be crucial to provide signals to induce
neurogenesis and cell cycle progression in the VZ progen-
itor population, either through direct contacts with radial
glia processes or due to its ability to stimulate FGF2 inter-
action with cell receptors. Crosstalk between different sig-
naling molecules and their cell receptors is necessary to
maintain cell differentiation and several extracellular
matrix proteins are known to facilitate these interactions.
In this context, it is important to stress that perlecan rep-
resents an important suppressor of vascular smooth mus-
cle cell proliferation [63] and of endothelial cell
migration [64]. Finally, we note that our findings may
have important implications to understand the pathology
of several human conditions, such as holoprosencephaly
[65], neuronal heterotopias [66] or microcephaly. Eluci-
dation of the molecular mechanisms controlling prolifer-
ation and differentiation of specific subsets of progenitor
cells in brain may lead to the development of strategies for




Perlecan gene was inactivated in mice by homologous
recombination in embryonic stem cells. As previously
demonstrated [4], deletion of the sixth exon of the perle-
can gene results in the lack of expression of perlecan pro-
tein. PCR was used to genotype offspring resulting from
perlecan heterozygous matings. We used two sets of oligo-
nucleotides for genotyping. The first set of primers, 5'-
AACCAGAAGGGGTGGCAAGAA-3' and 5'-GCAGCAC-
CTCTTGAATCTGAG-3', amplifies a fragment of 500 bp
between intron 5 and exon 6, which is absent in the per-
lecan mutants. The second set of primers, 5'-AACCA-
GAAGGGGTGGCAAGAA-3' and 5'-
TACTGAGGCAGAGTCTCTCTC-3', amplifies an approx.
1000 bp fragment between the intronic regions 5 and 6 in
the wild-type allele. In the perlecan mutant allele this frag-
ment is reduced to 500 bp. We used the same PCR condi-
tions for both sets of primers: denaturation at 94°C for 3
minutes, followed by 35 cycles at 94°C for 30 seconds,
60°C for 30 seconds, and 72°C for 45 seconds, and a final
step at 72°C for 3 minutes. Mice heterozygous for the
mutation appeared normal and did not display any overt
anatomical or behavioral abnormalities. Brains were
removed and either fixed in Carnoy (60% ethanol, 30%
chloroform, 10% acetic acid) or in 4% phosphate-buff-
ered paraformaldehyde (PFA), embedded in paraffin, and
sectioned at 6–7 μm. Sections were Nissl stained with cre-
syl violet.
All experimental procedures were in accordance with the
Spanish and European Union legislations, and were
approved by our Institutional Animal Care and Use Com-
mittees.
Immunohistochemistry
Primary antibodies used were: rabbit polyclonals: anti-
Sonic Hedgehog (1:50; Santa Cruz Biotech.), anti-Ki67
(1:50; Abcam, UK), anti-FGF2 (1:500; Santa Cruz Bio-
tech.), anti-Perlecan domain II (1:5,000; [67]), anti-phos-
pho-histone H3 (ser 10) (1:100; Upstate), anti-laminin-1
(1:100; Abcam, UK), anti-calbindin (1:5000; Swant); goat
polyclonal anti-Patched (1:50; Santa Cruz Biotech.);
monoclonals: anti-nestin Rat401 (1:4; Developmental
Studies Hybridoma Bank, Iowa), anti-PCNA (1:100; Santa
Cruz Biotech.), anti-Tbr1 (1:1000; R. Hevner, Seattle,
USA) and anti-BrdU (1:2500; Vector Laboratories, UK).
Fluorescent secondary antibodies included goat anti-rab-
bit IgG tetramethylrhodamine isothiocyanate (1:100;
Abcam, UK) and goat anti-mouse IgG Alexa488 and goat
anti-rat IgG Alexa488 (1:200; Molecular Probes). For non-
fluorescent immunohistochemistry we used the following
secondary antibodies: biotinylated anti-mouse IgG
(1:200; Vector Laboratories), biotinylated anti-goat IgG
(1:200; Vector Laboratories), and biotinylated anti-rabbitBMC Developmental Biology 2007, 7:29 http://www.biomedcentral.com/1471-213X/7/29
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IgG (1:200; Vector Laboratories). Immunostaining was
visualized by using the ABC Elite kit (Vector Laboratories)
and a solution of 3,3'-diaminobenzidine (Sigma) and
hydrogen peroxide. Images were obtained in a Zeiss Axio-
plan microscope equipped with an Axiocam camera or
with a Leica TCS SP confocal microscope equipped with
an Ar 488 laser and HeNe 543 and 568 laser lines. Confo-
cal analysis was performed in the SCIE, University of
Valencia and in the Instituto de Neurociencias de Ali-
cante.
BrdU experiments and apoptosis labeling and detection
To track proliferating cells, we injected dams intraperito-
neally with 5-bromo-2'-deoxyuridine (Sigma) at 40 mg/
kg of body weight. Embryos were collected at varying time
points (30 minutes, 2, 4 or 24 hours) after injection. After
a 30 min survival, BrdU labels cycling cells during S-
phase. Two hours survival marks cells until M-phase, and
four and 24 h survival allows the detection of S-phase cells
and some postmitotic neurons. The endpoints of migra-
tion of early neuronal cohorts were similarly studied, with
BrdU injections to dams at E12.5 and embryo collection
at E17.5. BrdU staining was performed on paraffin sec-
tions that had been pretreated to denaturate DNA (2 N
HCl for 30 min at 40°C and then neutralized in 0.1 M
sodium tetraborate). Apoptosis was analyzed on paraffin
sections of 4% PFA fixed brains by the terminal deoxynu-
cleotidyl transferase (TdT)-mediated dUTP nick end labe-
ling (TUNEL) method using a commercial in situ cell
death detection kit (Roche) according to the manufac-
turer's instructions.
Quantitative studies of regional growth of the 
telencephalon and of cell proliferation
To quantify brain size at E12.5–13.5, we measured the
cross-sectional area of each telencephalic region consid-
ered on two sets of three coronal sections for each embryo
at levels similar to those shown in Fig. 1B and 1E.
PCNA and Ki67 antibodies mark the same cells, namely
the progenitor population [25,26]. In the present study,
we initially immunostained such a population with a
mouse monoclonal antibody to PCNA. However, in some
experiments we used Ki67 antibodies instead of anti-
PCNA so that double-label immunofluorescence could be
performed along with anti-BrdU. We performed simulta-
neous immunofluorescence staining of Ki67 and BrdU
after survivals of 30 minutes, 4 hours or 24 hours post-
BrdU injection. We calculated the labeling index as the
number of BrdU+ cells divided by the number of Ki67+
cells in a given telencephalic region. Quitting fraction was
calculated in E12.5 embryos pulsed with BrdU and
retrieved 24 h later. The quitting fraction represents the
ratio of BrdU+, Ki67- cells (i.e., those that have left the
mitotic cycle) referred to the total number of BrdU+ cells.
Mitotic index was calculated as the number of phospho-
histone H3+  cells (cells in M phase) divided by the
number of Ki67+ cells in a given telencephalic region. We
counted phospho-histone H3+ cells in sections adjacent to
those where we counted Ki67+ cells. To compare the
extent of G2/M phase between wild-type and perlecan-
null E16.5 neocortex, pregnant mother were injected with
BrdU 2 h before killing and double labeling was per-
formed to reveal BrdU-positive nuclei as well as mitotic
cells containing phospho-histone H3, as has been
described [24]. We counted six areas in three sections for
each region of the analyzed brains. On each litter, we
compared mutant values with the mean value of two wild-
type embryos. Statistical significance was analyzed using
Student's t test.
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